Volume 31, Issue 4 (1-2023)                   JGUMS 2023, 31(4): 362-377 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Umrani A, Faghihi H, Mohammadi Z, Mirzabeigi P, Montazeri Ghods H, Rastegari A. Optimization of Xanthan Gum and Sorbitol Levels in the Mycophenolate Mofetil Powder for Oral Suspension. JGUMS 2023; 31 (4) :362-377
URL: http://journal.gums.ac.ir/article-1-2547-en.html
1- Department of Pharmaceutics and Pharmaceutical Nanotechnology, Faculty of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Clinical Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Pharmacognosy and Pharmaceutical Biotechnology, Faculty of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Full-Text [PDF 6275 kb]   (233 Downloads)     |   Abstract (HTML)  (907 Views)
Full-Text:   (244 Views)
Introduction
The mycophenolate mofetil powder for oral suspension, as an immunosuppressive agent, is widely administered in patients with kidney disorders and following organ transplantation in children [1]. Currently, the drug powder is not produced in Iran and, due to limitations in its import from other countries, the patients are in dire need of it. In this regard, by the use of available information and the patent of drug (Cellcept®, 5688529A, Roche company, US), we attempted to localize the production of this drug. Since in the patent, many excipients are used, the screening was conducted to assess the role of these excipients including xanthan gum, colloidal silicon dioxide, soy lecithin, sorbitol, citric acid, sodium citrate, methyl, and propyl paraben. The results of screening demonstrated the determining role of xanthan gum and sorbitol in the final quality and stability of the suspension. Sorbitol is widely used as sweetening agent and a viscosity enhancer in the suspension, and provide steric protection against interparticle agglomeration [23]. The rheological properties of xanthan gum and its ability to provide flocculated suspension, having desired stability in different ranges of pH, temperature, and shaking speed. It can also reduce destabilizing processes of two-phase systems such as Ostwald ripening and Coalescence [4, 5]. To further evaluate and determine the suitable amounts of these two excipients in the drug, experiments and response surface methodology were employed in this study. 
Methods
Central composite design (CCD) was used to study the interaction of xanthan gum (mg) and sorbitol (gr) as independent variables, while F value (sedimentation volume) of suspension, concentration of active pharmaceutical ingredient (API) after preparation and after storage (%) were considered as dependent variables (Table 1).


The design recommended 13 formulations with 10 g API, 25-75 mg xanthan gum, 10-25 g sorbitol, 500 mg colloidal silicone dioxide, 100 mg soy lecithin, 55 mg citric acid, 500 mg sodium citrate, 45 mg methyl paraben, 5 mg propyl paraben and purified water to adjust the volume to 50 mL. 
To prepare the samples, 10 g of API with determined amounts of xanthan gum, colloidal silicone dioxide, soy lecithin, and sorbitol were blended in a cubic blender for 15 minutes and then transferred into Sigma mixer. The water solution containing citric acid and sodium citrate was gradually added to the powder to provide the paste. The content was dried at a room temperature for 24 hours and then passed through an oscillatory granulator to prepare granules. Finally, distilled water containing preservatives and banana flavor was added to the prepared granules and the F value reached 50 mL. The F value of suspension was calculated by dividing final sediment volume by initial sediment volume after keeping suspension still for 3 days. The reversed-phase high-performance liquid chromatography was employed to assess the concentration of API after preparation and after 3 months of storage at 45 ͦC in the oven. The optimization was done based on defined criteria for each dependent variable presented in Table 1. Selected formulation was prepared three times and analyzed accordingly. The predicted error was calculated for all responses. The mean particle size and poly dispersity index (PDI) of optimum samples were characterized after preparation and storage.  
Results
The results of analysis for dependent variables are shown in Table 2.


The F value varied from 0.3 to 0.9 in prepared formulations. The results of analysis of variance regarding the P values and proposed quadratic model for this variable (F value) demonstrated that the increase in the amount of xanthan gum significantly increased the F value while the volume of sorbitol had no significant  effect on the F value (Table 2). The amount of API was preserved from 80 to 100% after preparation and 75-98% after storage. The suggested quadratic model for these two variables indicated that increase in the amount of xanthan gum significantly improved the preserved percentage of API, while the amount of sorbitol caused no significant improvement in the API preservation (Table 2). 
The optimum sample composed of 68.81 mg xanthan gum and 16.69 gr sorbitol with F value of 0.92, and API concentrations of 100% and 98% after preparation and after storage, respectively. The calculated predicter error was less than 5% for all study variables. The mean particle size and the PDI of optimum sample were 70.25 µm and 0.76 after preparation, and 75.50 µm and 0.94 after storage
Discussion
Formulation and processing of mycophenolate mofetil powder for oral suspensions have several challenges including physicochemical instability, pH-dependent solubility, sedimentation of particles, and effective taste masking [6]. The increase in the stability of suspension can be performed through inhibiting the system coagulation by inter-particle repulsion and reducing the speed of particle sedimentation by increasing the viscosity of the continuous phase [7]. Particle sedimentation can be considered as one of the most critical parameters which can affect the dose uniformity of the suspension [8].
 In this study, to prepare the mycophenolate mofetil powder for oral suspension, its different excipients were used of which xanthan gum and sorbitol significantly affected on the quality and stability of the product. Xanthan gum as the viscosity modifier and stabilizer was demonstrated to significantly enhance the F value of suspension and the protection of API concentration both after preparation and after storage for 3 months. The latter could be attributed to Xanthan gum’ ability for providing steric hindrance in particles and inhibiting crystal growth in the suspension [9]. There was no significant difference in particle sizes after preparation and after 3 months of storage at high temperature. The amount of sorbitol as sweetening agent and stabilizer had no significant effect on the sedimentation volume and protection of API concentration. The stability of the prepared formulation of mycophenolate mofetil powder was better compared to the previously prepared galenic suspension of mycophenolate mofetil using Ora-plus agent having 70% protected API after 28 days of storage at room temperature [10].
It can be concluded that the proposed formulation of mycophenolate mofetil powder with optimum amounts of xanthan gum and sorbitol has good stability. Higher amount of xanthan gum and moderate amount of sorbitol are recommended for preparing an optimal product.  

Ethical Considerations
Compliance with ethical guidelines

This study was approved by the Ethics Committee of Iran University of Medical Sciences (Code: IR.IUMS.REC.1399.1235). All ethical principles were observed in this study.

Funding
This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors. 

Authors' contributions
Study concept and design: Homa Faghihi, Amin Umrani, Hamed Montazeri Ghods. Acquisition, analysis, or interpretation of data: Homa Faghihi, Amin Umrani, Hamed Montazeri Ghods, Parastoo Mirzabeigi. Drafting of the manuscript: Homa Faghihi, Amin Umrani, Zohreh Mohammadi. Critical revision of the manuscript for important intellectual content: Homa Faghihi, Amin Umrani, Hamed Montazeri Ghods, Ali Rastegari. Statistical analysis: Homa Faghihi. Administrative, technical, or material support: Homa Faghihi, Amin Umrani, Hamed Montazeri Ghods, Parastoo Mirzabeigi. Study supervision: Homa Faghihi, Amin Umrani, Hamed Montazeri Ghods, Zohreh Mohammadi.

Conflicts of interest
The authors declare no conflict of interest.

Acknowledgements
The authors would like to thank the staff of Laboratory of pharmaceutical processes and the Skill lab of Iran University of Medical sciences and the Zahravi pharmaceutical company for their cooperation in checking the quality of prepared samples.


References
  1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47(2-3):85-118. [DOI:10.1016/S0162-3109(00)00188-0]
  2. Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. Scientific Reports. 2020; 10(1):16727.  [PMID] [PMCID]
  3. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. The Journal of Rheumatology. 2003; 30(7):1508-12. [PMID]
  4. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Reviews in Molecular Medicine. 2000; 2(4):1-23. [DOI:10.1017/S1462399400001769] [PMID]
  5. McMurray RW, Harisdangkul V. Mycophenolate mofetil: Selective T cell inhibition. The American Journal of The Medical Sciences. 2002; 323(4):194-6. [DOI:10.1097/00000441-200204000-00005] [PMID]
  6. Kim JM, Oh JW, Kim S, Rhu J, Lee JS, Kim KS, et al. Tablet or capsule form of generic mycophenolate mofetil (My-Rept®) after liver transplantation: a prospective randomized trial. Drug Design, Development and Therapy. 2019; 13:2187-93. [PMID] [PMCID]
  7. Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Paediatric use of mycophenolate mofetil. British Journal of Clinical Pharmacology. 2013; 75(1):45-59. [DOI:10.1111/j.1365-2125.2012.04305.x] [PMID] [PMCID]
  8. Li Y, Zhang D, Ash J, Jia X, Leone A, Templeton A. Mechanism and impact of excipient incompatibility: Cross-linking of xanthan gum in pediatric powder-for-suspension formulations. Journal of Pharmaceutical Sciences. 2019; 108(11):3609-15. [DOI:10.1016/j.xphs.2019.07.005] [PMID]
  9. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: A meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006; 82(11):1413-8. [DOI:10.1097/01.tp.0000242137.68863.89] [PMID]
  10. Venkataramanan R, McCombs JR, Zuckerman S, McGhee B, Pisupati J, Dice JE. Stability of mycophenolate mofetil as an extemporaneous suspension. Annals of Pharmacotherapy. 1998; 32(7-8):755-7. [DOI:10.1345/aph.17213] [PMID]
  11. Papuga K, Kaszubkiewicz J, Kawałko D. Do we have to use suspensions with low concentrations in determination of particle size distribution by sedimentation methods? Powder Technology. 2021; 389:507-21. [DOI:10.1016/j.powtec.2021.05.060]
  12. Johnston D, Gray MR, Reed CS, Bonner FW, Anderson NH. A comparative evaluation of five common suspending agents used in drug safety studies. Drug Development and Industrial Pharmacy. 1990; 16(12):1893-909. [DOI:10.3109/03639049009028346]
  13. Rouaz K, Chiclana-Rodríguez B, Nardi-Ricart A, Suñé-Pou M, Mercadé-Frutos D, Suñé-Negre JM, et al. Excipients in the paediatric population: A review. Pharmaceutics. 2021; 13(3):387.  [PMID] [PMCID]
  14. Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, et al. Preparation and physicochemical stability of liquid oral dosage forms free of potentially harmful excipient designed for pediatric patients. Pharmaceutics. 2019; 11(4):190. [PMID] [PMCID]
  15. Dash RP, Srinivas NR, Babu RJ. Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability. Drug Development and Industrial Pharmacy. 2019; 45(9):1421-9. [DOI:10.1080/03639045.2019.1640722] [PMID]
  16. Yu XL, Xiao CX, Guo LC. [Effect of D-sorbitol on Rheology of Aqueous Alumina Suspensions with Poly(Acrylic Acid) (Chinese)]. Journal of Inorganic Materials. 2011; 26:545-9. [DOI:10.3724/SP.J.1077.2011.00545]
  17. Comba S, Sethi R. Stabilization of highly concentrated suspensions of iron nanoparticles using shear-thinning gels of xanthan gum. Water Research. 2009; 43(15):3717-26. [DOI:10.1016/j.watres.2009.05.046] [PMID]
  18. Petri DFS. Xanthan gum: A versatile biopolymer for biomedical and technological applications. Journal of Applied Polymer Science. 2015; 132(23):1-13. [DOI:10.1002/app.42035]
  19. Campisi B, Chicco D, Vojnovic D, Phan-Tan-Luu R. Experimental design for a pharmaceutical formulation: Optimisation and robustness. Journal of Pharmaceutical and Biomedical Analysis. 1998; 18(1-2):57-65. [DOI:10.1016/S0731-7085(98)00175-7]
  20. Patel R, Patel N, Patel M. Design, development and optimization of new high performance thin-layer chromatography method for quantitation of Retapamulin in pharmaceutical formulation: Application of design of experiment. Separation Science Plus. 2020; 3(4):121-8. [DOI:10.1002/sscp.202070007]
  21. Faghihi H, Najafabadi AR, Vatanara A. Optimization and characterization of spray-dried IgG formulations: A design of experiment approach. Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2017; 25(1):22. [PMID] [PMCID]
  22. Alam A, Ahuja A, Baboota S, Gidwani SK, Ali J. Formulation and evaluation of pharmaceutically equivalent parenteral depot suspension of methyl prednisolone acetate. Indian Journal of Pharmaceutical Sciences. 2009; 71(1):30-4. [PMID] [PMCID]
  23. Nayak AK, Pal D, Pany DR, Mohanty B. Evaluation of spinacia oleracea L. leaves mucilage as an innovative suspending agent. Journal of Advanced Pharmaceutical Technology & Research. 2010; 1(3):338-41. [PMID
  24. Fahimi F, Baniasadi S, Mortazavi SA, Dehghan H, Zarghi A. Physical and chemical stability of mycophenolate mofetil (MMF) suspension prepared at the hospital. Iranian Journal of Pharmaceutical Research. 2012; 11(1):171-5. [PMID]
  25. Haghighi DM, Faghihi H, Darabi M, Mirmoeini MS, Vatanara A. Spray freeze drying to solidify Nanosuspension of Cefixime into inhalable microparticles.Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2022; 30(1):17-27. [PMID]
  26. Smith WC, Bae J, Zhang Y, Qin B, Wang Y, Kozak D, et al. Impact of particle flocculation on the dissolution and bioavailability of injectable suspensions. International Journal of Pharmaceutics. 2021; 604:120767. [PMID]
  27. Mirfakhraei Y, Faghihi H, Zade AHM, Darabi M, Vatanara A.  Optimization of Stable IgG formulation containing amino acids and trehalose during freeze-drying and after storage: a central composite design. AAPS PharmSciTech. 2019; 20(4):154.  [PMID]
  28. Fauchais P, Vardelle M, Goutier S, Vardelle A. Key Challenges and Opportunities in Suspension and Solution Plasma Spraying. Plasma Chemistry and Plasma Processing. 2015; 35(3):511-25. [DOI:10.1007/s11090-014-9594-5]
  29. Moreton RC. Commonly used excipients in pharmaceutical suspensions. In: Kulshreshtha A, Singh O, Wall G, editors. Pharmaceutical Suspensions. New York: Springer; 2009. [DOI:10.1007/978-1-4419-1087-5_3]
  30. Frederick KJ. Performance and problems of pharmaceutical suspensions. Journal of Pharmaceutical Sciences. 1961; 50(6):531-5. [PMID]
  31. Singhvi G, Hans N, Shiva N, Kumar Dubey S. Chapter 5 - Xanthan gum in drug delivery applications. In: Hasnain MS, Nayak AK, editors. Natural polysaccharides in drug delivery and biomedical applications. Cambridge: Academic Press; 2019. [DOI:10.1016/B978-0-12-817055-7.00005-4]
  32. Alhalmi A, Ali NH, Altowairi M, Almoiliqy M, Sharma B. Xanthan gum; its biopharmaceutical applications: An overview. World Journal Of Pharmacy And Pharmaceutical Sciences. 2018; 7(1):1536-48. [Link]
  33. Shayoub ME, Sami MA, Ali MS, Shaddad SA, Dawoud AH, Abdella MS, et al. Evaluation of guar gum as suspension agent in comparison with xanthan gum using metronidazole benzoate as model of drug to estimate the effects of temperatures and storage on its suspension ability. Journal of Global Biosciences. 2015; 4(6):2452-8. [Link]
  34. Verhoeven E, Vervaet C, Remon JP. Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: In vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2006; 63(3):320-30. [DOI:10.1016/j.ejpb.2005.12.004] [PMID]
  35. Berninger T, Dietz N, González López Ó. Water-soluble polymers in agriculture: Xanthan gum as eco-friendly alternative to synthetics. Microbial Biotechnology. 2021; 14(5):1881-96. [DOI:10.1111/1751-7915.13867] [PMID] [PMCID]
  36. Zatz JL, Yarus C. Stabilization of sulfamerazine suspensions by xanthan gum. Pharmaceutical Research. 1986; 3(2):118-21. [DOI:10.1023/A:1016301721900] [PMID]
  37. Zhang X, Liu J. Effect of Arabic gum and xanthan gum on the stability of pesticide in water emulsion. Journal of Agricultural and Food Chemistry. 2011; 59(4):1308-15. [DOI:10.1021/jf1034459] [PMID]
  38. Benmounah A, Khaled B, Khaled, Chelah K, Djemiat D. Effect of xanthan gum and sodium carboxymetylcellulose on the rheological properties and zeta potential of bentonite suspensions. Paper presented at: CFM 2017 - 23ème Congrès Français de Mécanique. August 2017; Lille, France. [Link]
  39. Newman AW, Vitez IM, Mueller RL, Kiesnowski CC, Findlay WP, Rodriguez C, et al. Sorbitol. In: Brittain HG, editor. Analytical profiles of drug substances and excipients. Cambridge : Academic Press; 1999. [DOI:10.1016/S0099-5428(08)60629-2]
  40. Lutomski DM, Gora ML, Wright SM, Martin JE. Sorbitol content of selected oral liquids. The Annals of Pharmacotherapy. 1993; 27(3):269-74. [PMID]
Review Paper: Research | Subject: Special
Received: 2022/07/13 | Accepted: 2022/10/15 | Published: 2022/11/16

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb